Wedbush Reiterates Outperform on Disc Medicine, Maintains $88 Price Target
Benzinga Newsdesk 4 months ago
NewsPrice TargetReiterationAnalyst Ratings
Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and maintains $88 price target.
Wedbush analyst David Nierengarten reiterates Disc Medicine (NASDAQ:IRON) with a Outperform and maintains $88 price target.